DE:J4I Stock Latest News
Company AnnouncementsSolvonis moves to add Portuguese sites to Phase 3 alcohol addiction trial2w ago
Company AnnouncementsSolvonis plans investor briefing as it advances pipeline in addiction and mental health3w ago
Company AnnouncementsSolvonis boosts equity base with admission of over 1.09bn new shares1M ago
Company AnnouncementsSolvonis Advances CNS Pipeline as Cash Tightens and New Funding Arrives1M ago
Company AnnouncementsSolvonis touts ketamine-based AUD candidate as data sharpen European and U.S. expansion plans1M ago
Company AnnouncementsSolvonis Wins Key European Patent for Next-Generation PTSD Drug SVN-1141M agoCompany AnnouncementsSolvonis Steps Up U.S. Investor Push With Water Tower Research Conference2M ago
Company AnnouncementsSolvonis’ SVN-015 Cleared for Further NIDA Studies in Stimulant Use Disorder2M ago
Company AnnouncementsSolvonis Wins U.S. Research Coverage as AUD Pipeline Targets Large CNS Market3M ago
Company AnnouncementsSolvonis advances esketamine thin-film AUD therapy with positive U.S. bridge data4M ago
Company AnnouncementsSolvonis Wins Shareholder Backing as It Advances CNS Drug Pipeline4M ago
Company AnnouncementsSolvonis Sets 2026 AGM as CNS Pipeline Advances5M agoCompany AnnouncementsSolvonis CSO to Present on Psychedelic Addiction Therapy at High-Profile NIH Forum6M ago
Company AnnouncementsSolvonis pivots strategy to carry lead AUD drug through Phase 3 amid sector tailwinds6M ago
Company AnnouncementsSolvonis taps Water Tower Research to lift U.S. profile and investor reach6M ago
Company AnnouncementsSolvonis Hails U.S. Mental Health Order as Tailwind for CNS Drug Strategy6M ago
Company AnnouncementsSolvonis wins second U.S. patent to deepen PTSD therapy IP6M ago
Company AnnouncementsSolvonis Wins Key U.S. Patent to Bolster PTSD Drug Pipeline7M ago
Company AnnouncementsSolvonis names patented PTSD drug candidate SVN‑114 as lead asset7M agoCompany AnnouncementsSolvonis Extends Novel SDRI SVN‑015 Into Depression After Positive Preclinical Results9M ago
